Vectus Biosystems Limited
Vectus Biosystems Limited (VBS.AX) Company Profile & Overview
Explore Vectus Biosystems Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Vectus Biosystems Limited (VBS.AX) Company Profile & Overview
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.